CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)), fully human, monoclonal antibody being developed as anti-LIGHT treatment for COVID-19 ARDS in hospitalized patients.
LIGHT is a newly recognized cytokine with inflammatory actions encoded by the TNFSF14 gene. LIGHT, like many cytokines, appears to be involved in the dysregulated immune response, or “cytokine storm”. Secreted by neutrophils, macrophages and other inflammatory cells during an immune system response to infection,
LIGHT has been shown to play a key role in viral pneumonia. Compared to other cytokines, LIGHT is unique as it has a dual mechanism of action; exerting its effects by activating both T Cells and B Cells as well as upregulating other inflammatory cytokines.
It plays an important role in regulating immune responses in the lung, gut and skin and is “upstream” (or proximal) in the inflammatory cascade to many well recognized cytokines like IL-1, IL-6, IL-10, IL-13, TNF and GM-CSF. It has also been implicated in promoting scar (fibrosis) formation in the lung after infection.
CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)), fully human, monoclonal antibody being developed as a treatment for Pediatric Crohn’s Disease.
CERC-002 is currently enrolling patients in a Phase Ib Escalating Dose, Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody CERC-002 in Adults With Moderate to Severe Active Crohn's Disease Who Previously Failed Treatment With an Anti-TNFα Agent, With and Without Loss of Function Mutations in Decoy Receptor 3 (Anti-LIGHT in Anti-TNFα-Resistant Crohn's Disease [TRaCk LIGHT]). This is a precursor trial before going into Pediatric patients.